NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Completed · Phase 3 · Has a placebo group

Conditions studied: Attention Deficit Hyperactivity Disorder (ADHD)

In brief

This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age in a laboratory classroom study.

Key facts

Study ID

NCT01835548

Run by

Neos Therapeutics, Inc

People needed

87

Starts

2013-07-01

Expected to finish

2014-07-01

Last updated by the study team

2018-01-17

Who can join

Age: 6 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Currently being treated for ADHD

You may not qualify if…

• Other psychiatric diagnoses
• Significant cognitive impairment
• Chronic medical illnesses
• Structural cardiac defects
• Significant abnormal lab tests
• Taking disallowed medications
• Positive drug test

Where it is running

• Florida Clinical Research Center — Bradenton, Florida, United States
• Florida Clinical Research Center — Maitland, Florida, United States
• Center for Psychiatry and Behavioral Medicine — Las Vegas, Nevada, United States
• Duke University — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.